A Closer Look At Pharmacologic Compounds For Painful Diabetic Peripheral Neuropathy
- Volume 27 - Issue 2 - February 2014
- 3414 reads
- 3 comments
The treatment of diabetic neuropathic pain is complex and often unsatisfactory clinical results plague the patient with diabetes and the treating physician. Historically, physicians have used systemic pharmacologic treatments with mixed results and undesirable side effects. These have included antidepressants, anticonvulsants, N-methyl-D-aspartate (NMDA) receptor antagonists and opiate analgesics.1
More recently, topical pharmacologic compounds have started to play a role in the treatment of patients with diabetic neuropathic pain. Topical treatments offer a new multimodal arm in addressing chronic pain states as the treatments have limited absorption and an excellent safety profile in comparison to the systemic treatment options.2 These options offer an advantage over many of the medications physicians have used historically and can also offer benefits as adjunctive treatments.
A consensus report from the International Association for the Study of Pain in 2010 suggested that topical analgesics may be beneficial in a setting of “localized neuropathic pain.”3 These topical medications are also beginning to serve as a treatment option for difficult to manage pain in patients with osteoarthritis, postherpetic neuralgia and complex regional pain syndrome.
When one applies the topical medications to the skin, they exert their analgesic action by increasing drug concentration locally at the application site with minimal systemic uptake and low serum concentration. Given the complexity of treating neuropathic pain, topical analgesic formulations that use multiple agents with varied mechanisms of action may increase the efficacy of pain treatment and improve the chances of successful therapy.2
A Closer Look At Topical Compounds
A variety of medications are in common use as topical pain treatments. These modalities include nonsteroidal anti-inflammatory drugs (NSAIDs), local anesthetics, capsaicin, tricyclic antidepressants, ketamine and gabapentin (Neurontin, Pfizer) with options for use alone or in combination. In one study, 5% topical lidocaine applied as a patch or in a medicated plaster formulation were as successful in treating diabetic neuropathy as oral pregabalin, showing a 65 to 66 percent favorable response rate.4
Adverse effects of these medications are minimal and avoid many of the complications associated with systemic treatments. Adverse effects of the topical treatments can include local skin rashes, itchiness and irritations.
Compounded creams and ointments of topical analgesics use mixtures of water, glycerin, propylene glycol, methylparaben and conventional emulsifiers as carriers of the active substance.4
The formulation we use in our treatment population is delivered through a vehicle that is a proprietary mixture of base components called Lipoderm ActiveMax (Professional Compounding Centers of America). This theoretically delivers a greater local response to the tissues by the active compounds included within the QmedRx diabetic peripheral neuropathy pain pharmaceutical topical cream, and effectively allows the delivery of a number of compounds simultaneously through the human skin. With this system, dosing accuracy and uniformity occur through a specific QmedRx pump bottle.
Case Studies In Using Compounds For Neuropathy
We would like to present three brief case presentations using identical pain compounds from the QmedRx Pharmacy. Each individual used an equal volume of pain cream three to four times per day on the bilateral lower extremities. The cream consisted of lidocaine 2%, prilocaine 2%, topiramate 2.5% and meloxicam 0.09%.